Phio Pharmaceuticals shares are trading higher after the company presented preclinical study data showing INTASYL treatment may be used to improve the anti-tumor response of NK cells.
Portfolio Pulse from Benzinga Newsdesk
Phio Pharmaceuticals presented preclinical study data showing that INTASYL treatment may improve the anti-tumor response of NK cells, leading to higher stock prices.

May 18, 2023 | 4:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals' stock is trading higher after positive preclinical study data on INTASYL treatment's potential to improve anti-tumor response.
Phio Pharmaceuticals' stock is likely to go up in the short term due to the positive preclinical study data showing the potential of INTASYL treatment to improve the anti-tumor response of NK cells. This news is highly relevant and important for investors as it indicates potential growth in the company's product pipeline and future revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100